CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.
Ombitasvir, Paritaprevir and Ritonavir tablets: Technivie
|M14-250||HCV||Phase 3||An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) with Ribavirin (RBV) in Adults with Chronic Hepatitis C Virus Genotype 4 Infection in Egypt|
|M11-665||HCV||Phase 3||A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered with Ribavirin (RBV) in Adults with Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-I)|
|M13-101||HCV||Phase 2||An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study|
|P15-336||HCV||PMOS||Drug use-results survey of paritaprevir/ritonavir/ombitasvir in patients infected with hepatitis C virus genotype 1 in Japan|
|P15-764||HCV||PMOS||Drug use-results survey in patients infected with hepatitis C virus genotype 2|
No results found